Publication: 3008

A Phase I and Randomized Placebo-Controlled Phase II Trial of Bevacizumab plus Dasatinib in Patients with Recurrent Glioblastoma (GBM): Alliance/NCCTG N0872
      QxMD      Google Scholar   
Citation:
Cancer vol 125 (21) 3790-3800
Year:
2019
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
9
Parents:
2274  
Children:
None
Program:
OGC
Primary Committee:
Neuro-Onc
Sec. Committees:
Health Outcomes    
Pharmas:
 
Grants:
UG1CA189823, U10CA180821, U10CA180882, U10CA180833  
Corr. Author:
 
Authors:
                             
Networks:
LAPS-MN026, LAPS-MO011, METROMIN, RI005, VA009   
Study
NCCTG-N0872
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
bevacizumab, dasatinib, Src family kinase inhibitors, recurrent glioblastoma, phase II trial